Related Experiment Video
Updated: Mar 15, 2026
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
[Therapy of Metastatic Non-small Cell Lung Cancer]
N Reinmuth1, A Gröschel2, C Schumann3
1Asklepios Fachkliniken München-Gauting, Thorakale Onkologie, Gauting.
Abstract:
Lung cancer accounts for the leading cause of cancer deaths in Germany and is characterized by early metastasis formation. The majority of patients with non-small cell lung cancer (NSCLC) will receive systemic therapy for treatment of their disease. Importantly together with the identification of targetable oncogenic alterations, systemic treatment of NSCLC has dramatically changed in recent years with the implementation of various new agents such as tyrosine kinase inhibitors, anti angiogenic agents, and immune modulating drugs. However, these new therapeutic options also challenge the treating physician since molecular, histologic, and clinical factors need to be considered for the clinical decision-making. Moreover, supportive therapy including bronchoscopic therapy has evolved. The following therapy recommendations will summarize the up-to date treatment strategies for metastatic NSCLC.
Insights
Lung cancer is Germany
Area of Science:
- Oncology
- Pulmonology
Background:
- Lung cancer leads to cancer deaths in Germany, often with early metastasis.
- Most non-small cell lung cancer (NSCLC) patients require systemic therapy.
- Recent advancements include targeted therapies like tyrosine kinase inhibitors and immunomodulatory drugs.
Purpose of the Study:
- To provide updated therapy recommendations for metastatic non-small cell lung cancer (NSCLC).
- To guide physicians in selecting treatments considering molecular, histologic, and clinical factors.
- To summarize evolving supportive and bronchoscopic therapies for NSCLC.
Main Methods:
- Literature review of recent advancements in NSCLC treatment.
- Analysis of current systemic therapy options including targeted agents and immunotherapy.
- Evaluation of evolving supportive and bronchoscopic care strategies.
Main Results:
- Systemic treatment for NSCLC has significantly evolved with new targeted and immune-based therapies.
- Clinical decision-making is complex, requiring integration of molecular, histologic, and clinical data.
- Supportive and bronchoscopic therapies have also advanced.
Conclusions:
- Updated recommendations are crucial for managing metastatic NSCLC effectively.
- Personalized treatment approaches are essential due to therapeutic advancements.
- Comprehensive care, including supportive measures, is vital for NSCLC patients.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy